Exploring the Efficacy of Eletriptan and Dexketoprofen Through HIT-6, MIDAS, Allodynia, and VAS Assessments in Migraine

Introduction: Migraine is a common and disabling neurological disorder, often managed with pharmacological treatments such as eletriptan, a serotonin receptor agonist, and dexketoprofen, a nonsteroidal anti-inflammatory drug (NSAID).This study compared the clinical effectiveness and patient-reported outcomes of these two medications in female migraine patients.Methods: A total of 40 female migraine patients were divided into two treatment groups: 18 received dexketoprofen, and 22 received eletriptan.Clinical assessments included the Headache Impact Test-6 (HIT-6), Migraine Disability Assessment (MIDAS), Allodynia Questionnaire, and Visual Analog Scale (VAS).Correlations among these measures were analyzed within each group, and Fisher's Z-test was used to compare correlation strengths.Results: The eletriptan group had significantly higher HIT-6 (p<0.001) and allodynia scores (p=0.002)than the dexketoprofen group.However, there were no significant differences in MIDAS and VAS scores between the groups.Correlation analysis showed a stronger association between HIT-6 and MIDAS in the eletriptan group (r=0.622)compared to the dexketoprofen group (r=0.491).HIT-6 and allodynia were significantly correlated in the dexketoprofen group, while HIT-6 and VAS were significantly correlated in the eletriptan group.Discussion and Conclusion: These findings suggest that eletriptan may be more effective for severe migraines associated with central sensitization, while dexketoprofen may be more beneficial for mild to moderate migraine cases.Understanding these differences can help guide personalized migraine treatment strategies.